The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Statsenko M.E.

Volgograd State Medical University

Streltsova A.M.

Volgograd State Medical University

Turovets M.I.

Volgograd State Medical University

Hepatocardial relationships in patients with arterial hypertension and non-alcoholic fatty liver disease: focus on cardiac remodeling

Authors:

Statsenko M.E., Streltsova A.M., Turovets M.I.

More about the authors

Journal: Russian Journal of Preventive Medicine. 2022;25(4): 61‑68

Read: 1072 times


To cite this article:

Statsenko ME, Streltsova AM, Turovets MI. Hepatocardial relationships in patients with arterial hypertension and non-alcoholic fatty liver disease: focus on cardiac remodeling. Russian Journal of Preventive Medicine. 2022;25(4):61‑68. (In Russ.)
https://doi.org/10.17116/profmed20222504161

Recommended articles:
The significance of exogenous nitrate and nitrite of plant origin for vascular health. Russian Journal of Preventive Medi­cine. 2024;(11):141-146
Cuffless methods of blood pressure measurements. Review of modern technologies. Russian Journal of Preventive Medi­cine. 2024;(12):156-162
Adapted scale for analysis of nece­ssary septal myectomy in aortic valve replacement. Piro­gov Russian Journal of Surgery. 2024;(12-2):35-41
Liver and bone in tandem: osteopenia as an inevitable companion to non-alcoholic fatty liver disease. Russian Journal of Evidence-Based Gastroenterology. 2024;(4):40-50
Modern aspe­cts of chro­nic cere­bral ischemia pathogenetic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):106-113

References:

  1. Younossi ZM. Non-alcoholic fatty liver disease — A global public health perspective. Journal of Hepatology. 2019;70(3):531-544.  https://doi.org/10.1016/j.jhep.2018.10.033
  2. Maurice J, Manousou P. Non-alcoholic fatty liver disease. Clinical Medicine. 2018;18(3):245-250.  https://doi.org/10.7861/clinmedicine.18-3-245
  3. Lazebnik LB, Golovanova EV, Turkina SV, Raikhelson KL, Okovityy SV, Drapkina OM, Maev IV, Martynov AI, Roitberg GE, Khlynova OV, Abdulganieva DI, Alekseenko SA, Ardatskaya MD, Bakulin IG, Bakulina NV, Bueverov AO, Vinitskaya EV, Volynets GV, Eremina EYu, Grinevich VB, Kazyulin AN, Kashkina EI, Kozlova IV, Konev YuV, Korochanskaya NV, Kravchuk YuA, Li ED, Loranskaya ID, Makhov VM, Mekhtiev SN, Novikova VP, Ostroumova OD, Pavlov ChS, Radchenko VG, Samsonov AA, Sarsenbaeva AS, Sayfutdinov RG, Seliverstov PV, Sitkin SI, Stefanyuk OV, Tarasova LV, Tkachenko EI, Uspensky YuP, Fominykh YuA, Khavkin AI, Tsyganova YuV, Sharhun OO. Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. Eksperimental’naya i klinicheskaya gastroenterologiya. 2021;185(1):4-52. (In Russ.). https://doi.org/10.31146/1682-8658-ecg-185-1-4-52
  4. Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Medicine. 2017;15(1):45.  https://doi.org/10.1186/s12916-017-0806-8
  5. Drapkina OM, Korneeva ON. Continuum of non-alcoholic fatty liver disease: from hepatic steatosis to cardiovascular risk. Racional’naya farmakoterapiya v kardiologii. 2016;12(4):424-429. (In Russ.). https://doi.org/10.20996/1819-6446-2016-12-4-424-429
  6. Wu S, Wu F, Ding Y, Hou J, Bi J, Zhang Z. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis. Scientific Reports. 2016;6:33386. https://doi.org/10.1038/srep33386
  7. Kobalava ZhD, Konradi AO, Nedogoda SV, Shlyakhto EV, Arutyunov GP, Baranova EI, Barbarash OL, Boitsov SA, Vavilova TV, Villevalde SV, Galyavich AS, Glezer MG, Grineva EN, Grinshtein YuI, Drapkina OM, Zhernakova YuV, Zvartau NE, Kislyak OA, Koziolova NA, Kosmacheva ED, Kotovskaya YuV, Libis RA, Lopatin YuM, Nebieridze DV, Nedoshivin AO, Ostroumova OD, Oshchepkova EV, Ratova LG, Skibitsky VV, Tkacheva ON, Chazova IE, Chesnikova AI, Chumakova GA, Shalnova SA, Shestakova MV, Yakushin SS, Yanishevsky SN. Arterial hypertension in adults. Clinical guidelines 2020. Rossijskij kardiologicheskij zhurnal. 2020;25(3):149-218. (In Russ.). https://doi.org/10.15829/1560-4071-2020-3-3786
  8. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;39(33):3021-3104. https://doi.org/10.1093/eurheartj/ehy339
  9. Zhao YC, Zhao GJ, Chen Z, She ZG, Cai J, Li H. Nonalcoholic Fatty Liver Disease: An Emerging Driver of Hypertension. Hypertension. 2020;75(2): 275-284.  https://doi.org/10.1161/HYPERTENSIONAHA.119.13419
  10. Dudinskaya EN, Tkacheva ON, Matchekhina LV, Kotovskaya YuV, Leonteva IV, Kovalev IA, Shkolnikova MA. Replicative cell ageing: the role of insulin resistance in patients with arterial hypertension. Arterial’naya gipertenziya. 2019;25(3):225-231. (In Russ.). https://doi.org/10.18705/1607-419X-2019-25-3-225-231
  11. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterology. 2006;6:33.  https://doi.org/10.1186/1471-230X-6-33
  12. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846-854.  https://doi.org/10.1002/hep.21496
  13. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart Journal. Cardiovascular Imaging. 2015;16(3):233-270.  https://doi.org/10.1093/ehjci/jev014
  14. Statsenko ME, Streltsova AM, Turovets MI. Effect of non-alcoholic fatty liver disease on arterial stiffness and risk of cardiovascular complications in patients with arterial hypertension. Arhiv vnutrennej meditsiny. 2020;10(4):296-304. (In Russ.). https://doi.org/10.20514/2226-6704-2020-10-4-296-304
  15. Boldueva SA, Leonova IA, Bykova EG, Trostyanetskaya NA. Prognostic value of the left ventricular hypertrophy for sudden cardiac death in patients with myocardial infarction. Arterial’naya gipertenziya. 2009;15(3):325-329. (In Russ.). https://doi.org/10.18705/1607-419X-2009-15-3-325-329
  16. Azzam H, Malnick S. Non-alcoholic fatty liver disease — the heart of the matter. World Journal of Hepatology. 2015;7(10):1369-1376. https://doi.org/10.4254/wjh.v7.i10.1369
  17. Kim NH, Park J, Kim SH, Kim YH, Kim DH, Cho GY, Baik I, Lim HE, Kim EJ, Na JO, Lee JB, Lee SK, Shin C. Heart. 2014;100(12):938-943.  https://doi.org/10.1136/heartjnl-2013-305099
  18. Ryu S, Chang Y, Kang J, Kwon MJ, Yun KE, Jung HS, Kim CW, Shin H, Sung KC. Relationship Between γ-Glutamyltransferase Levels and Left Ventricular Diastolic Dysfunction. Circulation Journal. 2017;81(6):823-830.  https://doi.org/10.1253/circj.CJ-16-1084

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.